TICKERNERD
Menu
ALZNALZNHealthcare · Biotechnology

ALZN Stock Forecast: Alzamend Neuro, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$1.75
+1.74% on the day

The 1 Wall Street analysts covering Alzamend Neuro, Inc. hold a median 12-month price target of $26 — +1385.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 14 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$8.3M
Ticker Nerd rank
33 / 100
Median analyst target
$26
Analysts covering
1
Revenue$0.0
Operating income−$3.0M
Net income−$3.0M
Free cash flow−$1.1M
Quarterly, 8 quarters to 31 July 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.4%
1M
+12.9%
YTD
−3.8%
1Y
−27.4%
From 52W high
−33.2%
From 52W low
+104.0%
$0.86
$2.62
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALZN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alzamend Neuro, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
93
Revisions
83
Accruals
57
Volatility
36
Quality
33
Issuance
27
Growth
26
Value
13
Momentum
12

Size (93): Smaller than most of the companies we track.

Momentum (12): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALZN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALZN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Oct 25Jan 26Apr 26Jul 26ALZNHigh $26Median $26Low $26

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $26Median $26High $26

The green dot is the last close — the median target sits +1385.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Aug 2026Ascendiant CapitalMaintainsBuy$25 → $26
22 Dec 2025Ascendiant CapitalMaintainsBuy—
22 Dec 2025Ascendiant CapitalMaintainsBuy$42 → $28
25 Sept 2025Ascendiant CapitalMaintainsBuy—
21 Aug 2025Ascendiant CapitalMaintainsBuy—
17 Mar 2025Ascendiant CapitalMaintainsBuy—
16 Dec 2024Ascendiant CapitalMaintainsBuy—
11 Nov 2024Ascendiant CapitalMaintainsBuy—
12 Apr 2023Maxim GroupInitiatesBuy$1.50
1 Oct 2021Ascendiant CapitalInitiatesBuy$8.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALZN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ALZN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Alzamend Neuro, Inc. returned −27.4% against +17.0% for the S&P 500, dividends included.

ALZN vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26ALZNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALZN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Alzamend Neuro, Inc. (ALZN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 81% of US stocks

Price / sales
—
Price / book
10.2×

Cheaper than 9% of US stocks

EV / EBITDA
−0.9×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−373.2%

Higher than 4% of US stocks

Return on assets
−164.0%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Alzamend Neuro, Inc. (ALZN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alzamend Neuro, Inc. has a market value of $8.3M and an enterprise value of $7.4M.

  • Revenue in the twelve months to 31 July 2026: $0.0.

  • Net income over the same four quarters: −$9.1M.

  • Free cash flow in the twelve months to 31 July 2026: −$6.8M.

  • Shares outstanding: 4.8M.

  • Trailing P/E: −0.7×; forward P/E: −2.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Alzamend Neuro, Inc. employs 4 people.

Statement figures: company filings via Twelve Data, four quarters to 31 July 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

ALZN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALZNAlzamend Neuro, Inc.$8.3M
33
CNSPCNS Pharmaceuticals, Inc.$8.3M
22
IMNNImunon, Inc.$8.2M
23
XCURExicure, Inc.$8.7M
45
SKYESkye Bioscience, Inc.$8.8M
36
TRAWTraws Pharma, Inc.$7.9M
48
SNGXSoligenix, Inc.$7.9M
25

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alzamend Neuro, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALZN news & analysis

Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC

PRNewsWire · 20 Aug 2026positive

Alzamend Neuro announced that an abstract reporting resting-state functional magnetic resonance imaging (fMRI) findings for AL001, its novel organic lithium salt, has been accepted for poster presentation at Neuroscience 2026, the Society for Neuroscience annual meeting held November 14–18, 2026, in Washington, DC. The poster, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI," will be presented in the Neuropsychiatric Disorders session (PSTR337) on Wednesday, November 18, 2026.

Why it matters — The acceptance of AL001's Phase 1/2A brain network data for presentation at a major neuroscience conference highlights independent scientific interest in the company's lead candidate and its clinical findings.

Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain

PRNewsWire · 18 Aug 2026positive

Alzamend Neuro announced that an abstract reporting pharmacokinetic imaging data for AL001, its novel organic lithium drug candidate, was accepted for an oral presentation at the ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR, to be held September 28–October 1, 2026 in Barcelona, Spain. The abstract, titled "Pharmacokinetics Imaging of Lithium at 7T – Results from a Phase 1/2A Clinical Trial with a Novel Organic Lithium Salt," was selected following competitive review and will be presented in the Proffered Papers oral session on September 29, 2026.

Why it matters — The acceptance of this first-of-its-kind Phase 1/2A pharmacokinetic imaging data for oral presentation at a major scientific workshop provides independent recognition and visibility for Alzamend's AL001 program.

Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending

PRNewsWire · 4 Aug 2026positive

Alzamend Neuro announced the initial closing of a Securities Purchase Agreement with Ault Lending, receiving $7.5 million in gross proceeds from the first tranche of its newly designated Series D Convertible Preferred Stock. The agreement provides for up to $25 million in total funding, with up to $17.5 million available through subsequent tranche closings to support clinical programs and working capital needs.

Why it matters — Alzamend watchers would want to know about the new financing arrangement, which provides initial capital and a potential source of additional funds for the company's clinical programs.

FAQ

Frequently asked questions about ALZN stock

What is the ALZN stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Alzamend Neuro, Inc. have a median 12-month price target of $26, with estimates ranging from $26 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALZN stock a buy right now?

Of the 1 analysts covering Alzamend Neuro, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alzamend Neuro, Inc. 33 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALZN?

As at 14 Sept 2026, Alzamend Neuro, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).

Will ALZN stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +1385.7% from the last close, and Ticker Nerd's factor model ranks Alzamend Neuro, Inc. 33 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALZN stock forecast for 2030?

No analyst covering Alzamend Neuro, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALZN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $26 over the next 12 months.

How has ALZN stock performed over the past year?

Alzamend Neuro, Inc. returned -27.4% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alzamend Neuro, Inc. do?

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and psychiatric disorders.

What is the latest news on ALZN?

The most recent item we track (PRNewsWire, 20 Aug 2026): "Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC". Alzamend Neuro announced that an abstract reporting resting-state functional magnetic resonance imaging (fMRI) findings for AL001, its novel organic lithium salt, has been accepted for poster presentation at Neuroscience 2026, the Society for Neuroscience annual meeting held November 14–18, 2026, in Washington, DC. The poster, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI," will be presented in the Neuropsychiatric Disorders session (PSTR337) on Wednesday, November 18, 2026.

Company

About Alzamend Neuro, Inc.

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and psychiatric disorders. Alzamend Neuro’s current pipeline centers on AL001, a patented ionic cocrystal formulation that combines lithium, proline, and salicylate, and ALZN002, a cell-based therapeutic vaccine candidate designed to help restore the immune system’s ability to combat Alzheimer’s disease. The company is working across major therapeutic areas including Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. Its research and development activities are directed toward advancing novel product candidates intended to address conditions with significant unmet medical need in neuroscience and mental health. Headquartered in Atlanta, Georgia, Alzamend Neuro plays a specialized role in the biotech market as a developer of investigational therapies focused on the central nervous system and immune-based approaches to Alzheimer’s disease.

CEO Mr. Stephan Jackman · 4 employees · United States · https://www.alzamend.com